- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
ABT
3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
5 Top Stock Trades for Thursday
A buyout for Ceasars? Earnings from Netflix, Abbott and Lam Research -- we've got it all covered in our top stock trades article.
ABT Stock Dips Following Q3 Earnings Results
ABT stock was down on Wednesday after the healthcare company released its earnings report for the third quarter of the year.
Abbott Laboratories Stock Gets a Boost From Q2 Earnings Beat
Abbott Laboratories (ABT) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018.
3 Big Stock Charts for Wednesday: United Technologies, Abbott Laboratories and Leggett & Platt
Stock charts of United Technologies, Abbott Laboratories and Leggett & Platt have earned a closer look as bullish trading prospects this morning.
Abbott Laboratories Stock Slips Despite Earnings Beat
Abbott Laboratories (ABT) stock as down on Wednesday despite the health care company reporting an earnings beat for the first quarter of 2018.
At $ 59.460, Abbott Laboratories (ABT) a Buy
The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and market intelligence.
Abbott Laboratories (ABT) a Buy This Week
The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and news.
Abbott Laboratories (ABT) a Buy at recent price of $63.22, on Robust Earnings Momentum
Portfolio Grader currently ranks ABT as a Buy. This analytical tool evaluates stocks by employing proprietary fundamental and quantitative analytical. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 4 months.
AbbVie Inc Dividend at Risk Amid Patent Protection Problems
ABBV remains a strong holding for dividend growth, but AbbVie is about to lose patent protection on Humira, which accounts for two-thirds of its revenue.
Abbott Laboratories (ABT) a Buy on Strong Earnings Momentum
The current recommendation of Buy for Abbott Laboratories (NYSE:ABT) has been derived by using Louis Navellier's investing methods and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 3 months.